

Advancements in Treatment for Major Depressive Disorder: From Medication to Therapy.

Holmes Pascal*

Department of Psychology, University of Bath, England, United Kingdom

Introduction

Major Depressive Disorder (MDD) is a pervasive mental health condition affecting millions worldwide, characterized by persistent sadness, loss of interest in activities, and various physical and cognitive symptoms. Over the past few decades, significant advancements have been made in the treatment of MDD, spanning medication, therapy, and innovative approaches. This article explores the evolution and current state of these treatments, emphasizing the importance of personalized care [1].

SSRIs, such as fluoxetine (Prozac) and sertraline (Zoloft), have been the cornerstone of MDD treatment since their introduction in the 1980s. They work by increasing serotonin levels in the brain, which helps improve mood and emotional regulation. SSRIs are favored due to their relatively mild side effect profile compared to older antidepressants like tricyclics and monoamine oxidase inhibitors (MAOIs) [2].

SNRIs, including venlafaxine (Effexor) and duloxetine (Cymbalta), target both serotonin and norepinephrine reuptake, providing a broader mechanism of action. They are often prescribed when SSRIs are ineffective, offering an alternative with a similar side effect profile. Medications such as bupropion (Wellbutrin) and mirtazapine (Remeron) do not fit neatly into the SSRI or SNRI categories. Bupropion, for example, affects norepinephrine and dopamine reuptake and is known for its activating effects, making it suitable for patients with fatigue and concentration issues [3,4].

Recent years have seen the introduction of ketamine and its derivative esketamine as rapid-acting antidepressants. Administered via intravenous infusion or nasal spray, these drugs can reduce depressive symptoms within hours. They are particularly beneficial for treatment-resistant depression, offering hope for patients who have not responded to traditional therapies. Advances in pharmacogenetics allow for more personalized medication choices based on genetic profiles. This approach can predict an individual's response to certain antidepressants, reducing the trial-and-error period often associated with finding the right medication [5,6].

CBT remains one of the most effective psychotherapies for MDD. It focuses on identifying and modifying negative thought patterns and behaviors. Numerous studies have demonstrated its efficacy, particularly when combined with

pharmacotherapy. IPT addresses interpersonal issues and their impact on depression. By improving communication skills and resolving conflicts, patients can experience relief from depressive symptoms. IPT is especially effective for individuals whose depression is triggered by relationship issues [7].

MBCT combines traditional cognitive therapy with mindfulness strategies. It teaches patients to be present and observe their thoughts without judgment, helping to prevent the recurrence of depressive episodes. MBCT is particularly effective for individuals with recurrent depression. Originally developed for borderline personality disorder, DBT has shown effectiveness in treating MDD, especially in individuals with high emotional dysregulation. It incorporates mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness skills [8].

TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It has been approved for patients with treatment-resistant depression and has shown promising results in reducing depressive symptoms with minimal side effects. Although it has been in use for decades, ECT remains one of the most effective treatments for severe depression, particularly when other treatments have failed. Advances in technique and anesthesia have improved its safety and reduced associated stigma [9].

VNS involves the use of a device implanted in the chest to send electrical impulses to the vagus nerve. It is used for treatment-resistant depression and has shown efficacy in reducing symptoms and improving mood. Research into psychedelics such as psilocybin (the active compound in magic mushrooms) and MDMA (ecstasy) has shown potential for treating MDD. These substances, when used in a controlled therapeutic setting, can provide profound insights and emotional breakthroughs that contribute to the alleviation of depressive symptoms [10].

Conclusion

The treatment landscape for Major Depressive Disorder has evolved significantly, offering a range of pharmacological, psychotherapeutic, and innovative options. While traditional treatments like SSRIs and CBT remain foundational, advancements in genetics, neuromodulation, and psychedelic therapy are opening new frontiers in personalized care. By

*Correspondence to: Holmes Pascal, Department of Psychology, University of Bath, England, United Kingdom, E-mail: pascalhs@uni.bath.uk

Received: 02-Mar-2024, Manuscript No. AACPCP-24-135126; Editor assigned: 04-Mar-2024, Pre QC No. AACPCP-24-135126 (PQ); Reviewed: 16-Mar-2024, QC No. AACPCP-24-135126; Revised: 23-Mar-2024, Manuscript No. AACPCP-24-135126 (R); Published: 30-Mar-2024, DOI:10.35841/aacpcp-8.1.167

embracing a holistic approach that combines these modalities, we can provide more effective and tailored treatments for individuals suffering from MDD, ultimately improving their quality of life.

References

1. Seaton CL, Bottorff JL, Oliffe JL. Mental Health Promotion In Male-Dominated Workplaces: Perspectives Of Male Employees And Workplace Representatives. *Psychol Men Masc.* 2019;20(4):541.
2. Edwards AM, Kotera Y. Mental Health In The UK Police Force: A Qualitative Investigation Into The Stigma With Mental Illness. *Int J Ment Health Addict.* 2021;19:1116-34.
3. Johnston MS, Ricciardelli R, McKendy L. Suffering In Silence: Work And Mental Health Experiences Among Provincial Correctional Workers In Canada. *Corrections.* 2021:1-9.
4. McCann TV, Lubman DI, Clark E. The Experience Of Young People With Depression: A Qualitative Study. *J Psychiatr Ment Health Nurs.* 2012;19(4):334-40.
5. Palpant RG, Steimnitz R, Bornemann TH. The Carter Center Mental Health Program: Addressing The Public Health Crisis In The Field Of Mental Health Through Policy Change And Stigma Reduction. *Prev Chronic Dis.* 2006;3(2).
6. Williams L, Gorman R, Hankerson S. Implementing A Mental Health Ministry Committee In Faith-Based Organizations: The Promoting Emotional Wellness And Spirituality Program. *Soc Work Health Care.* 2014;53(4):414-34.
7. Søvold LE, Naslund JA, Kousoulis AA, et al. Prioritizing The Mental Health And Well-Being Of Healthcare Workers: An Urgent Global Public Health Priority. *Front Public Health.* 2021;9:679397.
8. Kassen J. Beyond Burnout: Educators' Experiences Of Mental Health Issues, And Stigma In The Workplace.
9. Pinfold V, Toulmin H, Thornicroft G. Reducing Psychiatric Stigma And Discrimination: Evaluation Of Educational Interventions In UK Secondary Schools. *Br J Psychiatry.* 2003;182(4):342-6.
10. Hassanein AE. Promoting Mental Treatment in the Arab World.